Deciphering the nature of binding of dexlansoprazole with DNA: Biophysical and docking approaches
Int J Biol Macromol. 2022 Jul 27:S0141-8130(22)01609-9. doi: 10.1016/j.ijbiomac.2022.07.177. Online ahead of print.ABSTRACTDrugs, in general, exhibit their pharmacological activity in binding with intracellular targets. Numerous anticancer and antibacterial drugs target DNA as one of their primary intracellular targets. Dexlansoprazole (DLP) is a heterocyclic compound containing benzimidazole moiety and a proton pump inhibitor used to treat gastroesophageal reflux disease. The interaction of dexlansoprazole with calf thymus DNA (ct-DNA) has been studied using biophysical methods. The UV-Visible studies revealed a binding c...
Source: International Journal of Biological Macromolecules - July 30, 2022 Category: Biochemistry Authors: Anna Tanuja Safala Bodapati Bijaya Ketan Sahoo Ragaiahgari Srinivas Reddy Kandikonda Lavanya Shravya Rao Madku Source Type: research
Deciphering the nature of binding of dexlansoprazole with DNA: Biophysical and docking approaches
Int J Biol Macromol. 2022 Jul 27:S0141-8130(22)01609-9. doi: 10.1016/j.ijbiomac.2022.07.177. Online ahead of print.ABSTRACTDrugs, in general, exhibit their pharmacological activity in binding with intracellular targets. Numerous anticancer and antibacterial drugs target DNA as one of their primary intracellular targets. Dexlansoprazole (DLP) is a heterocyclic compound containing benzimidazole moiety and a proton pump inhibitor used to treat gastroesophageal reflux disease. The interaction of dexlansoprazole with calf thymus DNA (ct-DNA) has been studied using biophysical methods. The UV-Visible studies revealed a binding c...
Source: International Journal of Biological Macromolecules - July 30, 2022 Category: Biochemistry Authors: Anna Tanuja Safala Bodapati Bijaya Ketan Sahoo Ragaiahgari Srinivas Reddy Kandikonda Lavanya Shravya Rao Madku Source Type: research
Nocturnal acid breakthrough and esophageal acidification during treatment with dexlansoprazole as compared to omeprazole in patients with gastroesophageal reflux disease
ConclusionDexlansoprazole is more effective than omeprazole in suppressing gastric acid secretion, resulting in lesser EA and NAB, particularly in the presence ofH. pylori. (Source: Indian Journal of Gastroenterology)
Source: Indian Journal of Gastroenterology - June 30, 2022 Category: Gastroenterology Source Type: research
Addendum: Dexlansoprazole for GERD
Date: May 16, 2022
Issue #:
1650Summary:
A reader commented that our recent article on
Drugs for GERD and Peptic Ulcer Disease did not
include enough information on dexlansoprazole
(Dexilant, and generics), a proton pump inhibitor
(PPI) claimed to provide " all-day and all-night relief
from heartburn " . Dexlansoprazole recently became
available generically, but it is much more expensive
than other generic PPIs. (Source: The Medical Letter)
Source: The Medical Letter - April 29, 2022 Category: Drugs & Pharmacology Authors: admin Source Type: research
Acid Suppressant Therapy: a Step Forward with Potassium-Competitive Acid Blockers
AbstractPurpose of the reviewThe introduction of H2-receptor antagonists (H2RAs) and proton pump inhibitors (PPIs) into clinical practice has been a real breakthrough in the treatment of acid-related diseases. PPIs are now the standard of care for the treatment of gastroesophageal reflux disease (GERD), peptic ulcer disease (PUD),Helicobacter pylori infection, NSAID-associated gastroduodenal lesions, and upper gastrointestinal bleeding (UGIB). However, despite their effectiveness, PPIs display some intrinsic limitations, which underlie the unmet clinical needs that have been identified over the past decades.Recent findings...
Source: Current Treatment Options in Gastroenterology - January 25, 2021 Category: Gastroenterology Source Type: research
Efficacy and safety of 7 days versus 10 days triple therapy based on levofloxacin-dexlansoprazole for eradication of Helicobacter pylori: A pilot randomized trial
CONCLUSION: LAD 10 days is the least duration that provides maximum efficacy for H. pylori in Egyptian participants. In addition, successful treatment of H. pylori infection may reduce the risk of anemia and dyslipidemia. Furthermore, all members of the patient’s family should be screened for H. pylori to prevent recurrent infection. (Source: Indian Journal of Pharmacology)
Source: Indian Journal of Pharmacology - December 5, 2020 Category: Drugs & Pharmacology Authors: Noha Mahmoud Elkhodary Khaled Abdalkader Farrag Amany Mahmoud Elokaby Gamal Abd El-Hay Omran Source Type: research
The FDA-approved drugs ticlopidine, sertaconazole, and dexlansoprazole can cause morphological changes in C. elegans.
The FDA-approved drugs ticlopidine, sertaconazole, and dexlansoprazole can cause morphological changes in C. elegans.
Chemosphere. 2020 Dec;261:127756
Authors: Galford KF, Jose AM
Abstract
Urgent need for treatments limit studies of therapeutic drugs before approval by regulatory agencies. Analyses of drugs after approval can therefore improve our understanding of their mechanism of action and enable better therapies. We screened a library of 1443 Food and Drug Administration (FDA)-approved drugs using a simple assay in the nematode C. elegans and found three compounds that caus...
Source: Chemosphere - November 6, 2020 Category: Chemistry Authors: Galford KF, Jose AM Tags: Chemosphere Source Type: research
Cobalt ferrite magnetic nanoparticles as a highly efficient electrochemical platform for simultaneous determination of dexlansoprazole and granisetron hydrochloride
Publication date: December 2020Source: Microchemical Journal, Volume 159Author(s): Mona A. Mohamed, Nahla N. Salama, Maha A. Sultan, Hadeer F. Manie, Maha M. Abou El-Alamin (Source: Microchemical Journal)
Source: Microchemical Journal - August 29, 2020 Category: Chemistry Source Type: research
